Navigation Links
Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
Date:10/6/2008

SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) will host a conference call today, Monday, October 6, 2008 at 9:00 AM ET (6:00 AM PT) to review the outcome of the interim analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

Those interested may access the call with the following information:

Time: 9:00 AM ET/6:00 AM PT

Date: October 6, 2008

Dial-in: 1-877-419-6598 (domestic) or +1-719-325-4935 (international)

Webcast: http://www.dendreon.com (homepage and investor relations section)

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 888-203-1112 or 719-457- 0820 for international callers; the conference ID number is 5304314. The replay will be available from 2:00 pm ET on Monday, October 6, 2008 until midnight ET on Wednesday, October 8, 2008. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
11. ViroPharma to Present at Three Upcoming Healthcare Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...tCall/ -- Cyberonics, Inc. (Nasdaq: CYBX ) today ...utive Officer, and Greg Browne, Chief Financial Of...ay Health Care Conference in New York on Wednesday...e session and webcast will be audio only and no fo... host a webcast of the presentation live and by re...
(Date:11/20/2009)...swire-FirstCall/ -- BD (Becton, Dickinson and Comp... of its acquisition of HandyLab, Inc., an Ann Arbo...ctures molecular diagnostic assays and automation ...unced an exclusive agreement for BD to develop and...guar(TM) platform, the first fully integrated mole...
(Date:11/20/2009)...re-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Boa...wn as DOR BioPharma, Inc., a late-stage biotechnol...consortium to develop thermostable technology to a.... Soligenix received a $9.4 million grant from the...ases (NIAID), a division of the National Institute...
Breaking Medicine Technology:Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Dr M Group Selects Health Robotics Technology Over RIVA for all of its I V Compounding Centers in South East Asia 14017 1Dr M Group Selects Health Robotics Technology Over RIVA for all of its I V Compounding Centers in South East Asia 14017 2Dr M Group Selects Health Robotics Technology Over RIVA for all of its I V Compounding Centers in South East Asia 14017 3Dr M Group Selects Health Robotics Technology Over RIVA for all of its I V Compounding Centers in South East Asia 14017 4Communication problems in dementia care cause physical strain 57029 1Communication problems in dementia care cause physical strain 57029 2Diabetes drug kills cancer stem cells in combination treatment in mice 9909 1Diabetes drug kills cancer stem cells in combination treatment in mice 9909 2Diabetes drug kills cancer stem cells in combination treatment in mice 9909 3
...cation is June 3, 2009 - , , EXTON, Pa., Feb. 3 ...d (Nasdaq: VPHM ) today announced that the U.S. ...ority review for Cinryze C1 Inhibitor (human) as a...ema (HAE). The supplemental Biologics License App...1, 2008, was based on a re-analysis and resubmiss...
...ch designed to help improve medication adherence t..., WOONSOCKET, R.I., Feb. 3 /PRNewswire/ -- A s... found that nearly half of patients hospitalized f...d drug therapies, significantly increasing their r...s. The study found that among those patients who w...
Other Medicine Technology:FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE) 6CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 2CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 3CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year 4
(Date:11/20/2009)...ogist Closer to Understanding Brain Wiring and Dis...wire/ -- Dr. Jeremy Schmahmann, Professor of Neuro...the Massachusetts General Hospital in Boston, on T...esearch on the new field of study called "Connecti..., Dr. Schmahmann is an award-winning leader in t...
(Date:11/20/2009)...Nov. 20 The United Stat... to make essential changes its health reform bill ...funding and conscience protection on abortion, pro...ude strong provisions for adequate affordability. ...ll an "enormous disappointment" that creates new a...
(Date:11/20/2009)... Nov. 20 Rates of infect...ed in late October, but the pandemic flu virus con...age groups, including the elderly, according to a ...: DGX ), the world,s leading provider of diagnos...ts most recent Quest Diagnostics Health Trends(TM)...
(Date:11/20/2009)...ael, November 20 Cardio ...ww.CVSLMEDICAL.COM , a leading,developer of advanc...ced that,the company,s Board of Directors has deci...ada and the Far East for its proprietary next-gene...gioplasty (PCTA) procedures. , Cardio Vas...
(Date:11/20/2009)...v. 20 SIRIUS XM Radio ...dcast Doctor Radio Reports: What Every Women Ne... hosted by veteran journalist Perri Peltz. ,, ...19/NYTU044LOGO ) ,, Doctor Radio Reports: Wh...l air November 21 live at 10:00 am ET on Doctor ...
Breaking Medicine News(10 mins):Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5
...ecently approved of a new prescription treatment f...s almost everybody. Gingivitis is an inflammation ...ing gums. It is believed that plaque-forming bacte...uction in the inflammation associated with gingivi...
...rth weight may be at heightened risk// of cardiova...as well as for the fathers. In a research don...rt that poor fetal growth that leads to low birth ... children with low birth weight may also be at mor...
...cancers are preventable by changes in our life sty...osing excess weight also helps. To lose weight one...ncer Institute in US recently approved the dietary...ioxidants and protect the DNA from damage by free-...
...uggested that patients going for PET or CT scan sh...nterferes with PET/CT image results when there is ...university presented his study that looks at the ...l conference held this month in Toronto. Usua...
...er pills based treatment resulted in the lowest ra... the groups of African-Americans and Americans. No...ugs can benefit the patients with diabetes who suf...atment to Prevent Heart Attack Trial (ALLHAT) stud...
...f Internal Medicine obese women with breast cancer... study was conducted to determine treatment patter...nt chemotherapy for breast cancer. Adjuvant chemot... Data on patients with early stage breast canc...
Other Medicine News:Health News:Top Ten Super Food Items That Can Help In Avoiding Cancer , 2Health News:Obese women with breast cancer may be under treated., 2
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: